TrialNature communications2024

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.

Elena Giudice et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.